Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $110
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $110
Sarepta Therapeutics Is Maintained at Overweight by Piper Sandler
Sarepta Therapeutics Analyst Ratings
Analysts' Top Healthcare Picks: Sarepta Therapeutics (SRPT), Evolent Health (EVH)
Analysts Conflicted on These Healthcare Names: Apellis Pharmaceuticals (APLS), Skye Bioscience (SKYE) and Sarepta Therapeutics (SRPT)
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $157
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Announces Target Price $157
BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating
Sarepta Therapeutics (SRPT) Receives a Buy From Bank of America Securities
TD Cowen Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $203
Sarepta Therapeutics: Buy Rating Affirmed on Promising LGMD Program Progress and Regulatory Advancements
TD Cowen Reaffirms Their Buy Rating on Sarepta Therapeutics (SRPT)
Sarepta Therapeutics Analyst Ratings
Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $182
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $75
Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Cuts Target Price to $182
Sarepta Therapeutics Is Maintained at Overweight by Morgan Stanley
Sarepta Therapeutics Initiated at Overweight by Wells Fargo